Characterization of cytotoxic T lymphocyte function after foot-and-mouth disease virus infection and vaccination

Viral Immunology

Volumn 26, Issue 4, 2013, Pages 239-249

  Patch, Jared R ^a   Kenney, Mary ^a   Pacheco, Juan M ^a   Grubman, Marvin J ^a   Golde, William T ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FOOT AND MOUTH DISEASE VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; FOOT AND MOUTH DISEASE; HUMORAL IMMUNITY; LYMPHOCYTE FUNCTION; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE; VACCINATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TITRATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CRICETINAE; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; IMMUNITY, CELLULAR; SWINE; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VIRAL VACCINES; VIRUS SHEDDING;

EID: 84882748493     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2013.0011     Document Type: Article

References (58)

1. Arzt J, Pacheco JM, and Rodriguez LL. The early pathogenesis of foot-and-mouth disease in cattle after aerosol inoculation: Identification of the nasopharynx as the primary site of infection. Vet Pathol 2010;47:1048-1063.
2. Bablanian GM, and Grubman MJ. Characterization of the foot-and-mouth disease virus 3C protease expressed in Escherichia coli. Virology 1993;197:320-327.
3. Bautista EM, Ferman GS, and Golde WT. Induction of lymphopenia and inhibition of T cell function during acute infection of swine with foot and mouth disease virus (FMDV). Vet Immunol Immunopathol 2003;92:61-73.
4. Belsham GJ, and Brangwyn JK. A region of the 5' noncoding region of foot-and-mouth disease virus RNA directs efficient internal initiation of protein synthesis within cells: Involvement with the role of L protease in translational control. J Virol 1990;64:5389-5395.
5. Boysen P, and Storset AK. Bovine natural killer cells. Vet Immunol Immunopathol 2009;130:163-177.
6. Callahan JD, Brown F, Osorio FA, et al. Use of a portable real-time reverse transcriptase-polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus. J Am Vet Med Assoc 2002;220:1636-1642.
7. Carrillo C, Tulman ER, Delhon G, et al. Comparative genomics of foot-and-mouth disease virus. J Virol 2005;79: 6487-6504.
8. Charerntantanakul W, and Roth JA. Biology of porcine T lymphocytes. Anim Health Res Rev 2006;7:81-96.
9. Childerstone A, Cedillo-Baron L, Foster-Cuevas M, and Parkhouse R. Demonstration of bovine CD8 + T-cell responses to foot-and-mouth disease virus. J Gen Virol 1999;80:663-669.
10. Clarke BE, and Sangar DV. Processing and assembly of footand-mouth disease virus proteins using subgenomic RNA. J Gen Virol 1988;69:2313-2325.
11. de Avila Botton S, Brum MC, Bautista E, Koster M, Weiblen R, Golde WT, and Grubman MJ. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 2006;24:3446-3456.
12. Denyer MS, Wileman TE, Stirling CM, Zuber B, and Takamatsu HH. Perforin expression can define CD8 positive lymphocyte subsets in pigs allowing phenotypic and functional analysis of natural killer, cytotoxic T, natural killer T and MHC un-restricted cytotoxic T-cells. Vet Immunol Immunopathol 2006;110:279-292.
13. Devaney MA, Vakharia VN, Lloyd RE, Ehrenfeld E, and Grubman MJ. Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 component of the cap-binding protein complex. J Virol 1988;62:4407-4409.
14. Doel TR. FMD vaccines. Virus Res 2003;91:81-99.
15. Donaldson AI, Herniman KA, Parker J, and Sellers RF. Further investigations on the airborne excretion of foot-andmouth disease virus. J Hyg (Lond) 1970;68:557-564.
16. Gerner W, Hammer SE, Wiesmuller KH, and Saalmuller A. Identification of major histocompatibility complex restriction and anchor residues of foot-and-mouth disease virusderived bovine T-cell epitopes. J Virol 2009;83:4039-4050.
17. Golde WT, de Los Santos T, Robinson L, Grubman MJ, Sevilla N, Summerfield A, and Charleston B. Evidence of activation and suppression during the early immune response to foot-and-mouth disease virus. Transbound Emerg Dis 2011;58:283-290.
18. Grubman MJ, and Baxt B. Foot-and-mouth disease. Clin Microbiol Rev 2004;17:465-493.
19. Grubman MJ, Moraes MP, Schutta C, et al. Adenovirus serotype 5-vectored foot-and-mouth disease subunit vaccines: The first decade. Future Virol 2010;5:51-64.
20. Grubman MJ, Zellner M, Bablanian G, Mason PW, and Piccone ME. Identification of the active-site residues of the 3C proteinase of foot-and-mouth disease virus. Virology 1995;213:581-589.
21. Guzman E, Taylor G, Charleston B, and Ellis SA. Induction of a cross-reactive CD8( + ) T cell response following foot-and-mouth disease virus vaccination. J Virol 2010;84: 12375-12384.
22. Guzman E, Taylor G, Charleston B, Skinner MA, and Ellis SA. An MHC-restricted CD8 + T-cell response is induced in cattle by foot-and-mouth disease virus (FMDV) infection and also following vaccination with inactivated FMDV. J Gen Virol 2008;89:667-675.
23. Haydon DT, Bastos AD, Knowles NJ, and Samuel AR. Evidence for positive selection in foot-and-mouth disease virus capsid genes from field isolates. Genetics 2001;157:7-15.
24. Hutber AM, Kitching RP, Fishwick JC, Bires J. Footand-mouth disease: The question of implementing vaccinal control during an epidemic. Vet J 2011;188:18-23.
25. Joshi G, Sharma R, and Kakker NK. Phenotypic and functional characterization of T-cells and in vitro replication of FMDV serotypes in bovine lymphocytes. Vaccine 2009;27: 6656-6661.
26. Klump W, Marquardt O, and Hofschneider PH. Biologically active protease of foot and mouth disease virus is expressed from cloned viral cDNA in Escherichia coli. Proc Natl Acad Sci USA 1984;81:3351-3355.
27. Kuhn R, Luz N, and Beck E. Functional analysis of the internal translation initiation site of foot-and-mouth disease virus. J Virol 1990;64:4625-4631.
28. Mayr GA, Chinsangaram J, and Grubman MJ. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 1999;263: 496-506.
29. Mayr GA, O'Donnell V, Chinsangaram J, Mason PW, and Grubman MJ. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 2001; 19:2152-2162.
30. Moffat K, Howell G, Knox C, Belsham GJ, Monaghan P, Ryan MD, and Wileman T. Effects of foot-and-mouth disease virus nonstructural proteins on the structure and function of the early secretory pathway: 2BC but not 3A blocks endoplasmic reticulum-to-golgi transport. J Virol 2005;79:4382-4395.
31. Moffat K, Knox C, Howell G, et al. Inhibition of the secretory pathway by foot-and-mouth disease virus 2BC protein is reproduced by coexpression of 2B with 2C, and the site of inhibition is determined by the subcellular location of 2C. J Virol 2007;81:1129-1139.
32. Moraes MP, Diaz-San Segundo F, Dias CC, Pena L, and Grubman MJ. Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response. Vaccine 2011;29:9431-9440.
33. Moraes MP, Mayr GA, Mason PW, and Grubman MJ. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 2002;20:1631-1639.
34. Murphy FA, Gibbs EPJ, Horzinek MC, and Studdert MJ. Picornaviridae Veterinary Virology. Third ed. Academic Press, New York, NY, 1999;417-532.
35. Nfon CK, Ferman GS, Toka FN, Gregg DA, and Golde WT. Interferon-alpha production by swine dendritic cells is inhibited during acute infection with foot-and-mouth disease virus. Viral Immunol 2008;21
36. Nfon CK, Toka FN, Kenney M, Pacheco JM, and Golde WT. Loss of plasmacytoid dendritic cell function coincides with lymphopenia and viremia during foot-and-mouth disease virus infection. Viral Immunol 2010;23:29-41.
37. Pacheco JM, Brum MC, Moraes MP, Golde WT, and Grubman MJ. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 2005;337:205-209.
38. Pacheco JM, Butler JE, Jew J, Ferman GS, Zhu J, and Golde WT. IgA antibody response of swine to foot-and-mouth disease virus infection and vaccination. Clin Vaccine Immunol 2010;17:550-558.
39. Pacheco JM, and Mason PW. Evaluation of infectivity and transmission of different Asian foot-and-mouth disease viruses in swine. J Vet Sci 2010;11:133-142.
40. Pacheco JM, Tucker M, Hartwig E, Bishop E, Arzt J, and Rodriguez LL. Direct contact transmission of three different foot-and-mouth disease virus strains in swine demonstrates important strain-specific differences. Vet J 2012;193:456-463.
41. Patch JR, Pedersen LE, Toka FN, et al. Induction of footand-mouth disease virus-specific cytotoxic T cell killing by vaccination. Clin Vaccine Immunol 2011;18:280-288.
42. Pena L, Moraes MP, Koster M, et al. Delivery of a foot-andmouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine. Vaccine 2008;26:5689-5699.
43. Rock KL, Farfan-Arribas DJ, and Shen L. Proteases in MHC class I presentation and cross-presentation. J Immunol 2010; 184:9-15.
44. Rodriguez A, Ley V, Ortuno E, et al. A porcine CD8+ T cell clone with heterotypic specificity for foot-and-mouth disease virus. J Gen Virol 1996;77:2089-2096.
45. Rodriguez LL, and Grubman MJ.Foot and mouth disease virus vaccines. Vaccine 2009;27:D90-94.
46. Sanz-Parra A, Jimenez-Clavero MA, Garcia-Briones MM, Blanco E, Sobrino F, and Ley V. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Virology 1999;259:129-134.
47. Sanz-Parra A, Sobrino F, and Ley V. Infection with foot-andmouth disease virus results in a rapid reduction of MHC class I surface expression. J Gen Virol 1998;79:433-436.
48. Sanz-Parra A, Vazquez B , Sobrino F, Cox SJ, Ley V, and Salt JS. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of footand-mouth disease virus capsid proteins. J Gen Virol 1999; 80:671-679.
49. Scudamore JM, and Harris DM. Control of foot and mouth disease: Lessons from the experience of the outbreak in Great Britain in 2001. Rev Sci Tech 2002;21:699-710.
50. Sellers RF, and Parker J. Airborne excretion of foot-andmouth disease virus. J Hyg (Lond) 1969;67:671-677.
51. Smith DM, Lunney JK, Martens GW, et al. Nomenclature for factors of the SLA class-I system, 2004. Tissue Antigens 2005;65:136-149.
52. Sutmoller P, Barteling SS, Olascoaga RC, and Sumption KJ. Control and eradication of foot-and-mouth disease. Virus Res 2003;91:101-144.
53. Toka FN, Kenney MA, and Golde WT. Rapid and transient activation of gammadelta T cells to IFN-gamma production, NK cell-like killing, and antigen processing during acute virus infection. J Immunol 2011;186:4853-4861.
54. Toka FN, Nfon C, Dawson H, and Golde WT. Natural killer cell dysfunction during acute infection with foot-and-mouth disease virus. Clin Vaccine Immunol 2009;16:1738-1749.
55. Toka FN, Nfon CK, Dawson H, Estes DM, and Golde WT. Activation of porcine natural killer cells and lysis of footand-mouth disease virus infected cells. J Interferon Cytokine Res 2009;29:179-192.
56. Vakharia VN, Devaney MA, Moore DM, Dunn JJ, and Grubman MJ. Proteolytic processing of foot-and-mouth disease virus polyproteins expressed in a cell-free system from clone-derived transcripts. J Virol 1987;61:3199-3207.
57. Yang PC, Chu RM, Chung WB, and Sung HT. Epidemiological characteristics and financial costs of the 1997 foot-andmouth disease epidemic in Taiwan. Vet Rec 1999;145:731-734.
58. Yewdell JW, and Haeryfar SM. Understanding presentation of viral antigens to CD8 + T cells in vivo: The key to rational vaccine design. Annu Rev Immunol 2005;23:651-682.